Immunology and immunotherapy of human cancer: present concepts and clinical developments
|
|
- Angelica Butler
- 6 years ago
- Views:
Transcription
1 Critical Reviews in Oncology/Hematology 34 (2000) Immunology and immunotherapy of human cancer: present concepts and clinical developments Andreas J.A. Bremers, Giorgio Parmiani* Unit of Immunotherapy of Human Tumours, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, Milan, Italy Accepted 24 November 1999 Contents 1. Introduction Recognition of tumour cells by the immune system Tumour antigens T Lymphocytes Dendritic cells Natural killer cells Antibodies Evidence of tumour protection in vivo Tumour escape mechanisms Recognition and selection Downregulation of the immune response Tolerance induction Immunodeficiency in cancer patients Immunotherapy: background and rationale Non specific immunostimulation Cytokines Vaccination with molecularly defined antigens Defined antigens and antigen selection Peptide based vaccines Recombinant viral and bacterial vaccines DNA vaccination Idiotype antibody vaccination Vaccination with unidentified antigens Dendritic cells mediated vaccination Tumour cell based vaccination Heat shock protein vaccination The role of adjuvants Abbre iations: Ab, antibody; ADCC, antibody dependent cellular cytotoxicity; AJCC, American Joint Committee Cancer classification; APC, antigen presenting cell; BCG, Bacillus Calmette-Guérin; CEA, carcino embryonic antigen; CTL, cytotoxic T-lymphocytes; DC, dendritic cells; DTH, delayed type hypersensitivity; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for Research and Treatment of Cancer; FAC, 5 FU, adriamycin and cyclophosphamide; FasL, Fas ligand; 5 FU, 5 fluorouracil; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte macrophage-colony stimulating factor; HLA, human leukocyte antigen; HPV, human papilloma virus; HSP, heat shock proteins; IFN, interferon; IL, interleukin; LAK, lymphokine activated killer; MCG, Melanoma Cooperative Group; MHC, major histocompatibility complex; NK, natural killer; PBMC, peripheral blood mononuclear cells; TAA, tumour associated antigen; TCR, T cell receptor; TIL, tumour infiltrating lymphocytes; TNF, tumour necrosis factor. * Corresponding author. Tel.: ; fax: address: parmiani@istitutotumori.mi.it (G. Parmiani) /00/$ - see front matter 2000 Elsevier Science Ireland Ltd. All rights reserved. PII: S (99)
2 2 A.J.A. Bremers, G. Parmiani / Critical Re iews in Oncology/Hematology 34 (2000) Adoptive transfer Antibodies and bispecific antibodies Results of clinical studies Immune stimulants as single agents Bacillus Calmette-Guérin (BCG) Levamisole Other immunostimulating agents Cytokines Interleukin 2 (IL-2) Interferon (IFN) Other cytokines Combinations including cytokines Cytokines in isolated perfusion Vaccination Vaccination with defined antigens Peptide vaccination Idiotypic antibodies Recombinant vaccines Cell based vaccination Cell lysates Whole cells Gene-modified cells Allogeneic or accessory cell vaccines Heat shock protein (HSP) vaccination Dendritic cells based vaccination Adoptive transfer LAK cells Tumour infiltrating lymphocytes Antibodies Biochemotherapy Conclusion: immunotherapy, present and future Reviewers Acknowledgements References Biographies Abstract Immunotherapy of cancer is entering into a new phase of active investigation both at the pre-clinical and clinical level. This is due to the exciting developments in basic immunology and tumour biology that have allowed a tremendous increase in our understanding of mechanisms of interactions between the immune system and tumour cells. This review briefly summarizes the state of the art in basic tumour immunology before discussing the clinical applications of the new concepts in the clinical setting. Clinical approaches are diverse but can now be based on strong scientific rationales. The analysis of the available clinical results suggests that, despite some disappointments, there is room for optimism that both active immunotherapy (vaccination) and adoptive immunotherapy may soon become part of the therapeutic arsenal to combat cancer in a more efficient way Elsevier Science Ireland Ltd. All rights reserved. Keywords: Immunology; Immunotherapy; Human cancer 1. Introduction At the end of last century medical research was profoundly influenced by the impressive progress that had been made with the discovery of agents that cause infectious diseases, and the protective effect of the (humoral) immune system against these, as induced by vaccination. It is from this background of terminology and principles that the very first theories emerged, postulating the existence of a protective immune response against malignancies and the possibility to induce or augment such a response. In the 1890s Coley attempted to treat cancer patients with bacterial extracts that were supposed to diffusely boost the immune
3 A.J.A. Bremers, G. Parmiani / Critical Re iews in Oncology/Hematology 34 (2000) system [1]. As early as 1908, Paul Ehrlich proposed the concept of cellular immunity directed against malignancies, and successfully carried out vaccination with tumour antigens in animals [2]. Yet, today s tumour immunology was developed through enormous efforts in a history that was paved with disappointments rather than success [3]. Research activity in this field by generations of basic scientists, surgeons, and physicians, revealed that the immune system is a complex defence system that evolved to protect against microorganisms and not necessarily against tumours. To protect the body from self destruction by autoimmune disease, an unavoidable side-effect of the beneficial immune response, a number of safeguards turned out to exist that also shield tumours from the reaction of the immune system. In this article we will first analyse the possible mechanisms of tumour antigen presentation and the existing evidence that the immune system does play a role in the control of neoplastic diseases. Subsequently we will discuss the tumour escape mechanisms from the immune system. This information constitutes the basis for strategies that are judged to be potentially able to overcome the shortcomings of the immune system that are held responsible for the development of the neoplasm into a clinically detectable tumour. Finally, todays clinical achievements of immunotherapy will be summarised. 2. Recognition of tumour cells by the immune system Table 1 Categories of tumour associated antigen recognised by T lymphocytes in solid tumours Category of antigen Unique antigens Cancer testis antigens Tissue of origin related antigens, differentiation antigens Oncogene products Mutated tumour suppressor proteins Viral antigens Antigen (example of malignancy in which presence is common) Mutated catenin, CDK4, caspase 8, mutated HLA-A2 (melanoma, H&N, kidney) MAGE, BAGE and GAGE families, NY-ESO-1 (breast, melanoma, bladder, H&N) CEA (colon, breast, pancreas and others); gp100, TRP-2 and tyrosinase (melanoma) Mutated Ras (pancreas); Her2/neu (breast, ovary) p53 (breast, colon and others), APC (FAP syndrome), BRCA1 & 2 (familial breast cancer) Human papilloma virus (cervical cancer), hepatitis B virus (hepatocellular cancer) The immune system consists of a number of components. The traditional division is between humoral (antibody mediated) and cellular immune responses. One can also distinguish between an innate immunity and adaptive immunity. The innate immunity can discriminate between normal tissues belonging to the organism ( self ) and newly encountered non-self proteins or living cells. Thus, anything non-self, whether originating from viral infection, neoplastic transformation, or because it originates from another individual (as in transplantation), is recognised as such in a non-specific way, and attacked alike by non-specific effector cells like macrophages and natural killer (NK) cells. Adaptive immunity is the more complex system, aimed at the eradication of intracellular pathogens. To do this, antigens derived from such pathogens that are often new to the host organism, need to be recognised by receptor-bearing specialised immune cells which respond to a complex system of stimulatory and costimulatory signals. Both innate and adaptive immunity can contribute to a response to malignancies. For today s immunotherapeutical strategies the following components are of interest Tumour antigens For the adapti e immunity against tumours, antigens are needed to trigger a specific immune response. Ideal antigens should be able to elicit specific B or T cell responses or both, with T cell responses including recognition of HLA class II-restricted epitopes. Tumour associated antigens (TAA) that can be recognised on tumour cells by T lymphocytes form a heterogenous group (Table 1). They are generally divided into three categories [4,5]. The first consists of unique antigens that are specific for each single tumour, usually derived from mutated proteins, and can be recognised either by HLA class I or HLA Class II restricted T lymphocytes, according to their length and aminoacid sequence [4 6]. TAA shared with other tumours but predominantly expressed by malignancies form a second category; these are usually transcriptionally reactivated genes that are not normally expressed (e.g. genes from the MAGE family in various tumours and testicular tissue), previously known as embryonic antigens and recently referred to as cancer testis (CT) antigens. A third category is that of differentiation antigens derived from the tissue of origin of the tumour (e.g. gp100, Melan-A, and tyrosinase in melanomas). Surprisingly enough, these normal antigens turned out to include some of the TAA most frequently recognised by the immune system [4]. Yet other antigens, have been considered for immunotherapy of cancer. Examples of these are overexpressed antigens that are also present in normal tissues (e.g. CEA) [7]. Moreover, oncogene and tumour suppressor gene products that play an essential role in the development of malignancies, can generate epitopes able to induce immune
4 4 A.J.A. Bremers, G. Parmiani / Critical Re iews in Oncology/Hematology 34 (2000) T Lymphocytes Fig. 1. Endogenous processing of antigen and interactions between the cytotoxic T lymphocyte and the target cells. Protein is processed to become peptide fragments; peptides bind to empty MHC molecules, and this complex is transported to the cell surface, where it can be recognised by the appropriate T-cell receptor. Costimulatory molecule interactions are depicted on the left side. Most efforts put into the development of tumour immunology have focused on cytotoxic T lymphocytes (CTL) mediated immunity, since these cells are regarded as the most important effector cells against tumours. Recognition of tumour antigens by CTL is the result of a complex process (Fig. 1). In this system an antigen is processed inside the target or antigen presenting cell (APC) into small peptide fragments that are then presented at the cell surface within the groove of the Major Histocompatibility Complex (MHC, HLA in humans) Class I molecules. This complex is then recognised by a T cell receptor (TCR) present on CTL. This TCR must be fitting to both the HLA allele present on the cell, and to the peptide presented [11]. Though underestimated during the last few years, MHC Class II restricted recognition is also very important for the induction of antitumour CTL which are activated through a (CD4 mediated) T helper response [6]. The outcome of antigen recognition though, is not necessarily tumour cell killing. Inflammation or destruction, occurring during infection, come with cytokine-mediated signals (e.g. TNF- and GM-CSF), resulting in activation of T-lymphocytes. Lack of these signals may result in tolerance, as is usually the case for the majority of antigens physiologically present in the body Dendritic cells Fig. 2. Tumour escape mechanisms, and DC antigen presentation. (A) Tumour cell lacking MHC molecules; (B) tumour cell lacking antigen processing; (C) tumour cell lacking costimulatory molecule; and (D) DC featuring processing of tumour cell fragments, expressing epitope presenting surface MHC along with all the costimulatory molecules responses (e.g. mutated RAS, p53 [4 6]). Since some tumour histotypes, like pancreatic and lung cancers, bear such mutated genes with a high frequency, such antigens may represent interesting targets. Finally, viral products in virus associated tumours can deliver a potent and effective stimulus to the immune system (hepatitis B virus [8], Human papilloma virus 16 [9]). It is of note that only recently HLA class II-restricted epitopes have been clearly defined and that most of them belong to the unique group of antigens that derive by point mutation from already known proteins [10]. Costimulatory signals can be delivered by cytokines (see above) or by specific costimulatory molecules (e.g. B7.1, B7.2). The latter are typically, but not exclusively, present on APC like macrophages, monocytes, B-cells and dendritic cells (DC). Presentation of antigen to naive T-lymphocytes without co-stimulation may lead to T cell tolerance. In fact, the adequate antigen presentation to a naive immune system occurs through these APC [12]. With the possible exception of B-cell lymphoma, tumour cells seldom express costimulatory molecules. The most potent in terms of anti-tumour CTL induction is the APC subset known as DC [13]. Antigen expression on DC comes from endocytosis and processing of antigenic substances, ranging from soluble antigen to apoptotic cells. Subsequently the antigens are endogenously processed by the DC. This results in epitopes presented on the DC cell surface in the context of the autologous HLA alleles and costimulatory molecules (Fig. 2d). DC feature high amounts of the MHC molecules that are essential to CTL recognition. The vast expression of adhesion- and costimulatorymolecules, along with the production of T cell specific chemokines [14] are of essential importance for the
5 A.J.A. Bremers, G. Parmiani / Critical Re iews in Oncology/Hematology 34 (2000) microenvironment in which an effective immune response can be initiated: tumour cells that by themselves induce tolerance do evoke a potent immune response once fused with DC [15]. This essential difference caused by presentation through DC is also confirmed by in vivo experiments [16]. To activate this process of antigen presentation by the DC, the antigen has to be present, along with signals of tissue damage, the so-called danger signals. Heat shock proteins (HSP) that chaperone the important epitopes of a cell, can be regarded as such a signal, and from the available evidence it may be concluded that HSP constitute an important source of antigen for processing and presentation by DC under natural conditions [17]. Apart from their role in presentation of antigen to CTL, DC are also of importance in the induction of CD4 (T helper) and natural killer cell responses. This makes DC a central pivot of anti-tumour response, and implies great promises for clinical application Natural killer cells The cytolytic capacity of NK cells is well established. Research in recent years has revealed various mechanisms of these cells function that led to the conclusion that NK cells are part of the innate as well as of adaptive immunity. As a part of the innate immune system, these cells are licensed to kill malignant tissues or virus infected cells or HLA incompatible grafted cells that are recognised as being different from the normal self tissue. To obtain this selective effect, NK activity is usually inhibited by the autologous MHC class I allele, expressed on self tissue, through specialised receptors [18], though activating forms of receptors (mainly associated with HLA-C alleles) have also been identified. Many malignancies as well as virus infected cells however, also feature a downregulation of MHC class I [19,20], which then allows triggering of NK subsets, resulting in the killing of these targets. Of more recent date is the appreciation of the NK cell regulatory function within the adaptive immunity system. NK cells produce a wide array of cytokines, including IFN-, TNF-, GM-CSF, M-CSF, IL-2, IL- 3, IL-5 and IL-8. This cytokine profile of activated NK cells skews the helper T lymphocyte response and activates macrophages, and thus influences the development of the adaptive immune response [21]. NK cells have aso been shown to induce antibody production by B-cells and even function as antigen presenting cells to specific T cell clones in a MHC Class II restricted manner [22]. Moreover, absence of NK cells prevents the induction of CTL [21]. Thus, NK cells appear to play an important role in modulation of B- as well as in T-lymphocyte mediated immunity Antibodies Antibody dependent cellular cytotoxicity (ADCC) is an important tool in the eradication of intracellular pathogens and tumour cells. In such a case the antigens are expressed on the cell surface, usually in the form of a trans-membrane protein, and recognised by the antigen specific part of the antibodies. The tail of the antibody then binds to the Fc receptor on cells like NK cells and macrophages, resulting in a signal of activation that can cause the lysis of target cells. Naturally occurring antibodies with clinical relevance have been detected against tumour suppressor gene and oncogene products like p53 [23], K-Ras, Her2/neu [24], as well as other tumour antigens like CEA and EpCAM (own unpublished data). Some of the naturally occurring antibodies appear to be correlated with better prognosis, like SK-1 antibodies [25]and antibodies against TA90 [26], while those against EpCAM and p53 [23] can be associated with bad prognosis. 3. Evidence of tumour protection in vivo The immune system does undertake action against neoplastic disease. It has long been known that animals cured of their primary tumour by excision, appeared to be protected against it in subsequent tumour challenge experiments [27]. Moreover, patients with drug-induced prolonged immunosuppression after organ transplantation or due to severe immunodeficiency syndromes develop a higher frequency of several tumours. The immunologically best studied human malignancies are probably melanoma and renal cell carcinoma. MHC class I expression, allowing recognition of the tumour by the immune system, resulted in better clinical prognosis in melanoma [28], and loss of MHC class I or its defective function [29], in a worse prognosis [28]. Moreover, brisk infiltrate of primary melanoma is an independent prognostic factor [30], while the development of vitiligo as a consequence of an immune reaction to melanoma differentiation antigens has been reported to correlate with clinical response [31]. However, other tumours of which the immunogenicity is far less accepted, also appear to be able to provoke such protective responses. In colorectal cancer, CTL infiltration of tumours is associated with much better prognosis [32], and a correlation was shown between the T cell profile (impaired CD4 + counts) and progression of the disease [33]. Moreover, HLA class II expression by tumour cells, essential for the induction of T helper responses, appears to be associated with improved prognosis, at least in colorectal cancer [34].
6 6 A.J.A. Bremers, G. Parmiani / Critical Re iews in Oncology/Hematology 34 (2000) Tumour escape mechanisms According to the immune surveillance hypothesis, the expression of tumour antigens during neoplastic transformation would induce an immune response that can control tumour growth [35]. However, there is evidence from immunocrippled patients to support such a mechanism for only a fraction of tumours. In patients that underwent organ transplantation, and received long term immunosuppressive therapy, there is a high incidence of non-hodgkin lymphoma, renal cell cancer, Kaposi sarcoma, and uncommon carcinomas like lip, vulva, squamous skin carcinoma [36], all of which are of suspected viral origin. A modest but apparently significant increase was also found for melanoma and certain lung cancers. There is, however, no indication for immune surveillance for several of the major human neoplasms like colon or breast cancers. Several mechanisms have now been recognised that allow tumours to escape from an intact and otherwise competent immune system Recognition and selection Naturally occurring tumours are not monoclonal. An effective tumour recognition and cytotoxicity therefore constitutes a selective pressure towards cells that escape from the immune response. Thus, tumours have been found to develop in such a way that previously recognised antigens are no longer expressed, so-called antigen-loss variants [37,38]. Alternatively, selective survival may result in a tumour with defective antigen processing due to mutation in gene coding for molecules known to be crucial for antigen presentation and peptide transport to ER, like TAP (transporter associated with antigen presentation). The antigen is still present, but the recognised epitope will no longer appear at the cell surface in the MHC molecules [39] (Fig. 2b), resulting in disease progression [40]. Yet another escape route used is downregulation of MHC expression itself (Fig. 2a), thus inhibiting recognition by T-lymphocytes altogether [20] Downregulation of the immune response Under normal physiological conditions certain tissues like liver, eyes and testis can downregulate the immune response directed against these essential organs. This effect is obtained through local release of inhibitory molecules, e.g.tgf [41] and by expression of Fas Ligand (FasL) on the cell surface [42]. Interaction between these and the respective receptors or Fas molecule on the T-lymphocytes result in apoptosis of these effector cells. The expression of FasL has also been demonstrated on malignancies like melanoma [42], astrocytoma and glioblastoma [43], colon carcinoma [44], lung carcinoma [45], ovarian cancer [46] and oesophageal cancer [47], and thus may protect these tumours against activated lymphocytes. Alternatively, half of the tumours like lung and colon cancers were recently found to defend themselves against apoptosis by producing a soluble decoy receptor that binds to FasL on effector cells [48]. However, how effective this mechanism is during in vivo tumour growth is still to be established clearly. In fact, melanoma-specific T cell clones were found to be resistant to the FasL/Fas interaction [49] Tolerance induction Tumours are not only capable of reducing the impact of a cytotoxic reaction as outlined above, but can also activate mechanisms that cause immune recognition to result in tolerance. As described in previous sections, the presence of appropriate costimulatory molecules is obligatory if recognition is to result in cytotoxicity instead of anergy. Absence of costimulatory molecules on tumours can even prevent cytotoxic activation of CTL previously present [50,51], and may involve multiple factors [52]. Furthermore, evidence exists that anergy may emerge among CTL previously capable of effective recognition [53]. Finally, tumours may fail to provide the optimal danger signalling microenvironment and associated cytokines, which optimise the function of immune effector cells, as the primary process is neoplasm and not inflammation. One other factor of importance may be the localisation of APC. Basically, these should be able to process antigen from the tumour irrespective of the localisation, but it has been postulated that sensitisation of naive lymphocytes will only take place within the lymph node [54]; this is supported by clinical observation of generation of protective immune responses mounted only after lymph node metastasis occurred (Bremers et al., in preparation) Immunodeficiency in cancer patients All previous mentioned factors in tumour escape from the immune system may play a role at the tumour site. Other mechanisms of generalised diminished immunocompetence appear to be involved in cancer patients [55,56], which might have to do with malnutrition, immunosuppressive therapies, but also with other, not yet identified, factors. 5. Immunotherapy: background and rationale Many strategies have emerged in the course of development of cancer immunotherapy. The oldest approach
7 A.J.A. Bremers, G. Parmiani / Critical Re iews in Oncology/Hematology 34 (2000) was an effort to boost non-specifically the general function of the immune system (acti e non-specific immunostimulation), as initiated by Coley. He injected patients with bacterial toxins and obtained regression of solid neoplasms [1], probably through activation of cytokines. Some of these agents are in clinical use today. Most effort has been put in immunotherapy through the cellular immune system. Three different approaches have been devised. First, one can try to improve conditions for the function of the immune system in general, without actually altering the target or specific effector cells themselves. Examples of these are the administration of cytokines like interleukin-2 (IL-2) and interferon and (IFN-, IFN- ), though their effectivenes may in part be due to other, non-immunological, mechanisms too (see below). A second approach aims at the activation of the immune system by optimising the presentation of antigen: accination or acti e specific immunotherapy. Examples range from the application of synthetic peptides that represent single epitopes, to vaccination with viable whole tumour cells, the antigens of which can then be endogenously processed by professional APC. The third group of therapies, known as adopti e immunotherapy, employs the infusion of effector cells that have been stimulated to act against the tumour and/or expanded in vitro, like anti-tumour CTL or allogeneic lymphocytes after bone marrow transplantation. But even lymphocytes stimulated in vitro with IL-2 in the absence of tumour antigens (lymphokine activeated killer (LAK) cells) were used. This implies that adoptive transfer can be antigen specific (anti tumour CTL) or not (LAK) Non specific immunostimulation Agents belonging to this group have been evaluated for over a century now, and have, in some instances, been shown effective as a sole treatment or valuable as an adjuvant. Most of the agents originate from Coley s idea of stimulating the immune system as a whole by introducing bacterial agents, like BCG, Corynebacterium par um and others. Material from viral origin [57] and various chemical substances [58] have also been applied. With the exception of BCG that is also used as a single agent against superficial bladder cancer, these agents have been shown to be ineffective by themselves and are now employed as adjuvants with other forms of immunotherapy or chemotherapy Cytokines All cellular components necessary for an effective immune response against cancer are essentially present in individuals with a healthy immune system. Cytokines are transmitters that influence essential steps in the induction of the immune response in either qualitative or quantitative terms. This means that new reactions may occur, or weakly present ones may be augmented to become of significant importance. Many of the known human cytokines are now readily available at reasonable cost thanks to recombinant technology. Since application and evaluation are essentially identical to any pharmaceutical preparation, and much less labour intensive in clinical use compared to most other immunotherapeutical options, cytokines are attractive agents for clinical research and implementation. The number of trials with cytokines in cancer patients largely outnumbers any other form of immunotherapy, even though the studied malignancies are often relatively rare, e.g. renal cancer and melanoma. Cytokines are also used in combined strategies together with other treatment modalities. Insufficient concentration of appropriate cytokines is supposedly one of the reasons of failure of the immune system in tumour recognition and eradication. Adoptive transfer of effector cells or tumour vaccination alone is therefore thought to meet the same bottleneck. This is the rationale behind combinations of cytokine treatment (even through insertion of the appropriate gene in tumor cells) and vaccination or adoptive transfer. Though systemic toxicity is a problem with many cytokines [59 62] activity is mainly locoregional. This implies that a locoregional application allows much higher tissue concentrations in the treated tissue resulting in better outcome in clinical settings (see Section 6 for clinical results). A recent report has provided new insights in the possible mechanism by which cytokines like TNF- and IFN- may cause tumour-restricted disruption of tumour vasculature in isolated limb perfusion, via a reduced activation of the V 3 integrin that is expressed selectively on the proliferating tumour endothelium [63]. This form the rationale of isolated perfusions of limbs and liver [64,65], one of the important applications of cytokines, though biological systems to obtain local secretion of cytokines have been developed too [65]. Functions, as well as origins, of cytokines are generally complex. Frequently, the effect involves several other cytokines too. Most frequently tested in a clinical setting are IL-2, IFN-, IFN-, TNF-, and GM-CSF. Though excess IL-2 boosts mainly aspecific effector cell (LAK) activity, IL-2 is known to have a strong stimulating effect on T lymphocytes as well as NK cells. Interferons, like IFN- and IFN- play an important role in up- and down-regulation of oncogenes and suppression of cell replication, as well as having an anti-angiogenesis effect. IFN-, amongst others, is known to upregulate MHC expression and may increase vascular permeability.
8 8 A.J.A. Bremers, G. Parmiani / Critical Re iews in Oncology/Hematology 34 (2000) 1 25 TNF- has a depressing effect on CTL and NK cells but increases the function of monocyte and T-helper cells. It increases the permeability of the vascular bed and tumour infiltration [63,66]. GM-CSF is known to be involved with the maturation of various hematopoietic stem cells as well as the activity of mature effector cells, but most important is its essential role in DC maturation [67] Vaccination with molecularly defined antigens The essential task of vaccination is to activate the host s immune system. This should be achieved by offering the antigens that T lymphocytes can recognise in an optimally effective way, i.e. adequately presented and in the context of appropriate costimulatory signals Defined antigens and antigen selection In the development of tumour vaccines two different principles can be followed. One is to select antigens that are present on the tumour that is to be treated. Much effort has been put in identifying antigens and their epitopes with this objective in mind; in some instances, as in melanoma, a large [4] but as yet incomplete [68] number of TAA could be identified. Some TAA represent physiologically important proteins that are generally (over)expressed in malignancies; therefore, these would be ideal targets for vaccines that could be used on a large scale. This approach has many advantages, also in respect to cost, and safety of production. It may result in perseverant effectiveness in spite of ongoing selective pressure if the antigens (proteins) represent an essential determinant in carcinogenesis, e.g. RAS, and p53. However, when vaccinating with normal proteins, one risk is to generate a cross reactivity against normal tissues, and hence, auto-immune disease. As discussed above, tumours tend to be individual also in terms of antigen expression [4]. This has led to the introduction of vaccination strategies in which the individual (autologous) tumour cells are used to prepare a vaccine. This however is a very laborious and demanding procedure, requiring specialised laboratory facilities. One good example of a TAA suitable for the first type of vaccine is wild type p53, which is prevalent among a great variety of tumours, while being expressed in normal tissues too. Selective tumour eradication may be obtained through targetting of such proteins in malignancies. Instead, mutant p53 and the mutated RAS require a vaccine the antigens of which match with the mutation present in the individual tumour. A more restricted specificity can be obtained by using antigens that represent proteins expressed only in certain tissues or groups of tissues. Examples of these are the CEA for colorectal and other epithelial tumours, and her-2/neu for breast and ovary cancers. In these examples too, tumour specificity depends on overexpression rather than expression of a mutated protein. As mentioned before, TAA have been identified that are restricted in their expression to certain malignancies (Table 1). If a viral agent is involved in a crucial step of carcinogenesis, it may constitute a valuable source of target antigens of non-self origin. Thus, tumours like hepatocellular carcinoma and cervical carcinoma, could be controlled by vaccination with hepatitis B virus and Human Papilloma Virus (HPV) respectively Peptide based accines The ideal vaccine should present no more antigens than necessary to obtain the desired immunological reaction. The most pure antigen containing vaccine would be multiple synthetic peptides that may contain only oligopeptide epitopes of TAA which can be recognized by the patient s immune system in an HLA-restricted way. To cover a wide range of HLA types, the vaccine should be either HLA type matched or contain a cocktail of epitopes for the various HLA alleles. The goal is to load these peptides onto MHC molecules of APC in vivo; more specifically, binding to MHC on other normal tissue was shown to result in tolerance [69] that, in turn, can cause a better tumour outgrowth [16]. In the context of the right costimulation, as it occurs in the presence of DC, this can be avoided [16]. Peptide vaccination is proven to be effective against viral antigens [70] and in tumour challenge experiments in animals [71]. Clinical investigations have shown interesting results (Section ). However, some problems exist in tumour escape through selection at short notice [72] and the discrepancy between the occurrence of peptide specific CTL and clinical outcome [9,55] Recombinant iral and bacterial accines Recombinant techniques give the opportunity to introduce antigens or just epitopes (eventually along with costimulatory molecules and cytokines) into viral vectors. Viral infection and resulting tissue damage should, according to the danger theory, attract professional APC necessary for adequate antigen presentation. Direct infection of APC could result in endogenous processing. Improved presentation in Class I [73] or Class II [74] HLA, and effective introduction of costimulatory molecules [75] have all been shown to improve antigen presentation. Though circulating cross reacting neutralising antibodies recognising the viral vector constitute a major problem at the moment, particularly in adenovirus vectors, this approach seems very promising. A number of bacterial strains suitable for recombinant engineering like Salmonella [76], BCG [77] and Listeria Monocytogenes [78], have two characteristics that seem very attractive for vaccination: enteric route
9 A.J.A. Bremers, G. Parmiani / Critical Re iews in Oncology/Hematology 34 (2000) of application, and endogenous processing through infection of APC. Results in animal models are promising [79] DNA accination Naked DNA vaccines encoding tumour antigens have been shown to result in some degree of systemic tumour protection in animal experiments [80], but they lack the amplification and generation of danger signals that can be elicited with virus vaccines. Yet, some degree of inflammation and attraction of APC [81] and presentation by such cells [82] have been reported. Mechanisms involved in this type of immunisation remain largely unclear Idiotype antibody accination The idiotype is the variable binding part of an antibody, and fits like a mould to the antigen. When vaccinating with TAA specific antibody, this will give rise to the formation of autologous antibodies against the vaccine. The variable part of these induced antibodies fit to the mould, and therefore strongly resemble the TAA. Thus, the TAA (mimic) is available for recognition by the immune system in a completely different environment. This system has two advantages. It allows vaccination without the need for significant quantities of the purified antigen. Second, but also of great practical importance, it allows the induction of a response against non-protein antigens [83].This strategy has now reached the stage of clinical trials Vaccination with unidentified antigens The less defined the antigenic substances to be recognised by the immune system, the larger is the portion of the tumour cell needed tot include sufficient relevant antigens in the vaccine. In fact, many vaccines involve whole tumour cells. The use of malignant tissue as the crude base from which the vaccine is produced can be expected to increase the risk of side effects. Synthetic preparation of such a vaccine is impossible, and likely to remain so in the future. Cost of vaccination can be expected to grow along with the complexity of the vaccine. The use of such autologous vaccines in the form of whole tumour cells, lysates, apoptotic cells, or heat shock protein extracts has one major advantage: the vaccine represents the whole spectrum of unique and shared antigens expressed by the individual tumour. Thus, the possibility to induce an immune response with a variety of antigens expressed also on the target is increased, and the risk of tumour escape is theoretically reduced Dendritic cells mediated accination For reasons outlined above, DC are now believed to play a central role as APC in tumour immunology. Several methods have been devised, and found successfull, to load the MHC molecules of the DC with appropriate epitopes, often employing the endogenous antigen processing pathway of these APC. These methods range from pulsing with peptides [84], protein [85], cell lysates [86], through cross priming with apoptotic cells [87], fusion with whole tumour cells [15], RNA [88] or transfection with viral vectors [89]. The distinct advantages of using peptides, implying a restricted numbers of antigens, have been discussed above. Using the whole antigenic repertoire of the tumour may lead to stimulation of different T lymphocyte precursors, resulting in a larger repertoire of effector lymphocytes, both CD8 and CD4. Moreover, the application of a larger array of antigens theoretically reduces the chance of selection and tumour escape. Several unanswered questions need to be answered in order to optimise this type of treatment strategies. What are known as DC are a heterogeneous set of cells sharing some morphologic, functional, and surface antigen features [90], but subsets might have considerable differences in respect to other characteristics and functions. Endocytosis of antigens by bone marrow derived APC is followed by endogenous processing and subsequent presentation by both MHC Class II and I [12,87]. Introduction or augmentation of antigen production by tumour cells, e.g. by gene transduction, can lead to increased antigen presentation by the DC through processing of the tumour cell (fragments). Alternatively, one may choose to load the MHC on APC with antigens (peptide, soluble antigen) exogenously. It is also not clear which of the several antigen loading tactics is preferable, in vivo or in vitro. Considerable differences between methods used to obtain DC (bone marrow or peripheral blood derived, the employment of leukapheresis, G-CSF or GM-CSF+IL-4 stimulation, either in vivo or in vitro) call for comparison in respect to effects and efficacy. Results so far are certainly encouraging further exploration in the field of DC based strategies, since clinical trials have shown both antigen specific and clinical responses in, e.g. B-cell lymphoma [85] and melanoma [91] (Section for details) Tumour cell based accination Whole cells, either live irradiated transduced with different genes, dead, or lysed have been employed in vaccines. Of course these may be obstructed in their effect by the very reasons why the tumour itself did not provoke an adequate immune response in the first place. Attempts to overcome this by adding adjuvants, like BCG, to tumour cell based vaccines, as explained
10 10 A.J.A. Bremers, G. Parmiani / Critical Re iews in Oncology/Hematology 34 (2000) 1 25 below, turned out to be effective at least with immunogenic tumours. One reason may be that the used irradiated tumour cells go into apoptosis and are subsequently presented by autologous DC through cross priming. BCG was shown to play an additional role by stimulating maturation of DC [92]. More sophisticated approaches came with genetic modification technologies, that allowed, both in mice and humans, to introduce allogeneic MHC genes into the tumour cells [93], even in vivo [94], in an attempt to enhance immunogenicity. The latest in this field is the introduction of cytokine genes [95] or costimulatory molecules (e.g. B7) [96] into the genome of the vaccine tumour cells. This should then modify micro environmental conditions in the area of tumour cells in such a way that anergy is overcome and tumour lysis takes place [95,97]. One promising example of this is GM-CSF [98]. This is known to contribute to the maturation of DC, and can therefore enhance antigen presentation by the tumour cells also in vivo Heat shock protein accination HSP like hsp70 and 96 are naturally occurring intracellular substances that are supposed to chaperone a wide [99], possibly the full array, of antigenic proteins present in the cell, channelling these into both the MHC Class I and II processing pathway even in APC [100]. HSP are also related to signals associated with tissue damage, signalling danger and thus triggering DC mediated antigen presentation. Isolation of these immunological adjuvants from the tumour [99] thus obviates the need for antigen identification in a particular patient or of composing a cocktail of epitopes from TAA the individual tumour might be carrying, without the need for a vaccine composed of viable cells. Evidence exists for receptor mediated endocytosis of HSP by macrophages and DC. Vaccination with these HSP in animal models can thus induce CTL mediated systemic antitumour immunity [101]. The practical importance of HSP is supported by the observation that immunogenicity of tumour cells is related to HSP 70 they release [102]. Reviewing the existing evidence, one can even conclude that HSP are the predominant source of antigen in the natural setting [16] The role of adju ants Not only the choice of peptides, but also that of the adjuvant seems of crucial importance; amongst others the adjuvant used appears to be able to skew the induced immune response into one direction or another. Few tumour cell based vaccines have reached the phase III trial stage. Generally, these studies are combined with an adjuvant of bacterial nature (immune stimulants) to boost the specific immune response [103,104], though other mechanisms, like improved DC maturation may be involved here. Another promising strategy in adjuvant composition is aimed at a transient block of the inhibition of the T-cell response. The best studied example is the CTLA- 4, known to cause inhibition of T cell function to help terminate the immune reaction, thus interfering with T-cell and lymphokine activation [105]. By blocking such molecule one can potentiate cancer vaccines [106] Adopti e transfer In adoptive transfer selected effector cells are infused into the patient. This can be done systemically, or locally into the tumour. The effector cells have been expanded in vitro, as to evade mechanisms that inhibit expansion in vivo. The effector cells may be antigen specific (CTL) or non-specific LAK cells. Several trials have been conducted employing these strategies, as reviewed below. The source of the effectors can be the tumour, as in tumour infiltrating lymphocytes (TIL) or peripheral blood mononuclear cells (PBMC). PBMC are easier to obtain, but tumour-specific lymphocyte precursor frequency can be expected to be much lower in the blood than at the tumour site. Generally, autologous lymphocytes have to be used, since allogeneic cells can be rapidly rejected by the host. Moreover, allogeneic cells will attack normal tissues, inducing a graft versus host type of reaction. However, it has also been demonstrated that the transplanted allogeneic immune cells can recognize malignant cells as being non-self and mount a therapeutic response known as graft-versus-disease effect. By depletion of subsets of cells, the graft-versus-disease effect remains intact, whereas no graft-versus-host effect occurs [107,108]. This principle of preferential malignancy killing by certain subsets of allogeneic bone marrow cells is now being further evaluated for its use in solid tumours Antibodies and bispecific antibodies Monoclonal antibodies against antigens strongly expressed on tumour cells are capable of inducing tumour infiltration by lymphocytes [109] and Fc receptor mediated cytotoxicity [110]. This effect has been evaluated in some trials, demonstrating in vivo efficacy, as outlined below. By the use of Her2/neu transgenic mice, i.p. injection of an anti-her2 antibody resulted in the inhibition of tumour growth in 50% of animals [111]. Bispecific antibodies, with specificity for both target antigens and antigens on effector cells, can be used as a guide to the target for the effector cells [112].
11 A.J.A. Bremers, G. Parmiani / Critical Re iews in Oncology/Hematology 34 (2000) Results of clinical studies Several hundreds of immunotherapy trials have been reported on, the majority dating from the latest decade. Many of these have been phase I and phase II trials. At the first glance, most of the reports appear disappointing, featuring limited clinical responses (10 20%), often at the cost of considerable toxicity (Table 2). However, the majority of studies have been carried out in patients with advanced and often disseminated disease, where no sensible alternative treatment was available. This casts a shadow on the majority of the available studies since, as outlined above, disseminated disease causes immunosuppression, and advanced disease implies a long period of selective pressure in the direction of tumour escape mechanisms. In fact, some phase III studies, that were able to include earlier stages of disease, show results that can match or improve those of much more toxic chemotherapy, as demonstrated below (Table 3) Immune stimulants as single agents These constitute a heterogeneous group of agents that were found capable of modulating immune responses in an unspecific way, and generally by unknown mechanisms. This however does not detract to the fact that some were found usefull in the therapy of cancer Bacillus Calmette-Guérin (BCG) BCG is undoubtebly the best known agent from this group. BCG injection was found to result in cytokine secretion and activation of DC, which may explain for its possible antitumour effect. BCG as a single agent therapy is probably best known from its widespread use in superficial bladder cancer. Phase III studies have shown that BCG after surgery reduces the recurrence risk by 45%, similar or superior to mitomycin C [113]. In treatment of recurrences, BCG improved 5 year disease free survival from 17 to 37% in infiltrating tumours and from 18 to 45% in carcinoma in situ [114]. In many other malignancies however, including melanoma, it proved to have no Table 2 Highest degree of toxicity regularly encountered during various forms of immunotherapy No/minor toxicity Moderate toxicity Severe toxicity BCG, levamisole, OK432, OK42, GM-CSF, cytokines in isolated perfusion, peptide vaccination, tumour cell vaccination, heat shock protein vaccination (preliminary), DC vaccination Interferons, low dose IL-2, IL-6, IL-12 High dose IL-2, TNF-, LAK therapy, TIL therapy, antibodies (rare) effect, as demonstrated in prospective randomised phase III trials [115]. In malignant melanoma, adjuvant BCG after surgery is not beneficial in stage I and III (AJCC), whereas the effect in stage II remains controversial in several studies [116]; oral BCG monotherapy and intralesional BCG are effective, mainly in cutaneous metastasis, but without impact on the overall survival [116] Le amisole Another widely used agent belonging to this group is Levamisole. Though its application application in Dukes C colorectal carcinoma adjuvant treatment was ineffective, the combination with 5 FU reduced the risk of recurrence by 41% and overall death rate by 33% (at a rather short median follow up of 3 years) [117]. These figures compare favourably with the combination of 5 FU and folinic acid (FA) [118]. Toxicity was identical to that of 5 FU alone [117]. Based on these results the NIH recommended this treatment as standard choice of therapy in the adjuvant treatment of colon cancer [119], though subsequent studies did not completely confirm these results and some modifications of this regimen have been proposed based on 5FU and FA, particularly in Dukes C patients [120]. No antitumour activity of levamisole was found in melanoma patients Other immunostimulating agents As stated before, other immunostimulating agents of various origins have been described and used. Among the most studied are OK 432. Picibanil or OK-432 is a lyophilised preparation of inactivated Streptococcus Pyogenes, that is known to augment non-specific T cell cytotoxicity, LAK activity [121] and tumoricidal activation of macrophages. In the compiled results of two phase III studies from the same investigators, an with two arms and a total of 137 patients and another with three arms (immunotherapy, chemotherapy, surgery only) for a total of 330 gastric cancer patients, the addition of OK-432 to standard surgery and chemotherapy almost doubled 5 year survival time, compared to surgery (24%) and surgery plus chemotherapy (29%), to become 45% [56]. However, a more detailed evaluation of this treatment at 5-year casts doubts on its clinical impact since the same authors reported a survival of only 6% higher than the control group [122]. The influences on cytokine levels responsible for the effect of OK-432 were investigated only recently in melanoma patients, and were found to involve IL-1, TNF and IFN- [123]. In a placebo controlled prospective randomised trial in 64 patients with high risk non metastatic breast cancer, sodium dithio carbonate, applied as an adjuvant treatment in conjunction with the FAC regimen after modified radical mastectomy (vs FAC+operation
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationCANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University
CANCER IMMUNOPATHOLOGY Eryati Darwin Faculty of Medicine Andalas University Padang 18 Mei 2013 INTRODUCTION Tumor: cells that continue to replicate, fail to differentiate into specialized cells, and become
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationM.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology
Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationBiological Therapies for Cancer: Questions and Answers
Biological Therapies for Cancer: Questions and Answers Key Points Biological therapies use the body s immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments
More informationTumor Immunology. Tumor (latin) = swelling
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
More informationACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY
ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY The recognition of specific antigen by naïve T cell induces its own activation and effector phases. T helper cells recognize peptide antigens through
More informationChapter 22: The Lymphatic System and Immunity
Bio40C schedule Lecture Immune system Lab Quiz 2 this week; bring a scantron! Study guide on my website (see lab assignments) Extra credit Critical thinking questions at end of chapters 5 pts/chapter Due
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationC. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC.
Immunology - Problem Drill 13: T- Cell Mediated Immunity Question No. 1 of 10 1. During Antibody-dependent cell mediated cytotoxicity (ADCC), the antibody acts like a bridge between the specific antigen
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationLYMPHOCYTES & IMMUNOGLOBULINS. Dr Mere Kende, Lecturer SMHS
LYMPHOCYTES & IMMUNOGLOBULINS Dr Mere Kende, Lecturer SMHS Immunity Immune- protection against dangers of non-self/invader eg organism 3 components of immune system 1 st line: skin/mucosa/cilia/hair/saliva/fatty
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationFOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1
1 Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF FOCiS 2 Lecture outline Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory
More information1. Overview of Adaptive Immunity
Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive
More informationThe Immune System. These are classified as the Innate and Adaptive Immune Responses. Innate Immunity
The Immune System Biological mechanisms that defend an organism must be 1. triggered by a stimulus upon injury or pathogen attack 2. able to counteract the injury or invasion 3. able to recognise foreign
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationTCR, MHC and coreceptors
Cooperation In Immune Responses Antigen processing how peptides get into MHC Antigen processing involves the intracellular proteolytic generation of MHC binding proteins Protein antigens may be processed
More informationRationale for Patient- Specific Vaccine Therapy for Non-Hodgkin Lymphoma
Rationale for Patient- Specific Vaccine Therapy for Non-Hodgkin Lymphoma Maribeth Hohenstein, RN, BSN, OCN Clinical Research Nurse Coordinator University of Nebraska Medical Center Objectives Review the
More informationImmunology CANCER IMMUNOLOGY
Immunology د. عائدة الدرزي Lec. 6 CANCER IMMUNOLOGY Oncogenesis (passes through two stages): 1- Reversible change Normal transformed cells 2- Irreversible change Transformed oncogenic cells Factors causing
More informationLESSON 2: THE ADAPTIVE IMMUNITY
Introduction to immunology. LESSON 2: THE ADAPTIVE IMMUNITY Today we will get to know: The adaptive immunity T- and B-cells Antigens and their recognition How T-cells work 1 The adaptive immunity Unlike
More informationTitle: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS
LECTURE: 14 Title: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS LEARNING OBJECTIVES: The student should be able to: Describe the general morphology of the NK-cells. Enumerate the different functions
More informationAdaptive immune responses: T cell-mediated immunity
MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,
More informationImmunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia
Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer
More informationIndex. neurosurgery.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A A Complimentary Trial of an Immunotherapy Vaccine Against Tumor-specific EGFRvIII (ACTIVATE), 90 91 Active immunotherapy, 5 8, 96. See
More informationThere are 2 major lines of defense: Non-specific (Innate Immunity) and. Specific. (Adaptive Immunity) Photo of macrophage cell
There are 2 major lines of defense: Non-specific (Innate Immunity) and Specific (Adaptive Immunity) Photo of macrophage cell Development of the Immune System ery pl neu mφ nk CD8 + CTL CD4 + thy TH1 mye
More informationCELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.
!! www.clutchprep.com CONCEPT: OVERVIEW OF HOST DEFENSES The human body contains three lines of against infectious agents (pathogens) 1. Mechanical and chemical boundaries (part of the innate immune system)
More informationImmunology for the Rheumatologist
Immunology for the Rheumatologist Rheumatologists frequently deal with the immune system gone awry, rarely studying normal immunology. This program is an overview and discussion of the function of the
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationAdvances in Cancer Immunotherapy
Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain
More informationOncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationAllergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.
Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared
More informationThird line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!
Topic 8 Specific Immunity (adaptive) (18) Topics - 3 rd Line of Defense - B cells - T cells - Specific Immunities 1 3 rd Line = Prophylaxis via Immunization! (a) A painting of Edward Jenner depicts a cow
More informationInteraction between the immune system and tumor
Tumor immunology Interaction between the immune system and tumor elimination (immune system attempts to kill cancer cells and inhibits tumor growth) balance (between elimination and growth of tumor cells)
More informationSEVENTH EDITION CHAPTER
Judy Owen Jenni Punt Sharon Stranford Kuby Immunology SEVENTH EDITION CHAPTER 16 Tolerance, Autoimmunity, and Transplantation Copyright 2013 by W. H. Freeman and Company Immune tolerance: history * Some
More informationCampbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System Multiple-Choice Questions
Campbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System 24.1 Multiple-Choice Questions 1) The body's innate defenses against infection include A) several nonspecific
More informationGeneral Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center
General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationSpontaneous. Tumour induction. Immunosuppression
Tumor immunology is the study of : 1- The antigenic properties of the tumor cells 2- The host IR to these tumor cell 3- The immunologic consequences to the host of the growth of the malignant cells 4-
More informationCellular Pathology of immunological disorders
Cellular Pathology of immunological disorders SCBM344 Cellular and Molecular Pathology Witchuda Payuhakrit, Ph.D (Pathobiology) witchuda.pay@mahidol.ac.th Objectives Describe the etiology of immunological
More informationMon, Wed, Fri 11:00 AM-12:00 PM. Owen, Judy, Jenni Punt, and Sharon Stranford Kuby-Immunology, 7th. Edition. W.H. Freeman and Co., New York.
Course Title: Course Number: Immunology Biol-341/541 Semester: Fall 2013 Location: HS 268 Time: Instructor: 8:00-9:30 AM Tue/Thur Dr. Colleen M. McDermott Office: Nursing Ed 101 (424-1217) E-mail*: mcdermot@uwosh.edu
More informationTest Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas
Test Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas Chapter 04: Antigen Recognition in the Adaptive Immune System Test Bank MULTIPLE CHOICE 1. Most T lymphocytes
More informationImmune System AP SBI4UP
Immune System AP SBI4UP TYPES OF IMMUNITY INNATE IMMUNITY ACQUIRED IMMUNITY EXTERNAL DEFENCES INTERNAL DEFENCES HUMORAL RESPONSE Skin Phagocytic Cells CELL- MEDIATED RESPONSE Mucus layer Antimicrobial
More informationEffector T Cells and
1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New
More informationAttribution: University of Michigan Medical School, Department of Microbiology and Immunology
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution
More informationAdaptive Immunity. Jeffrey K. Actor, Ph.D. MSB 2.214,
Adaptive Immunity Jeffrey K. Actor, Ph.D. MSB 2.214, 500-5344 Lecture Objectives: Understand role of various molecules including cytokines, chemokines, costimulatory and adhesion molecules in the development
More informationImmunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells
Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard
More informationThe Adaptive Immune Response: T lymphocytes and Their Functional Types *
OpenStax-CNX module: m46560 1 The Adaptive Immune Response: T lymphocytes and Their Functional Types * OpenStax This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution
More informationTime course of immune response
Time course of immune response Route of entry Route of entry (cont.) Steps in infection Barriers to infection Mf receptors Facilitate engulfment Glucan, mannose Scavenger CD11b/CD18 Allows immediate response
More informationMucosal Immune System
Exam Format 100 points - 60 pts mandatory; 40 points where 4, 10 point questions will be chosen Some open-ended questions, some short answer. Kuby question Cytokines Terminology How do cytokines achieve
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationThe next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)
The next steps for effective cancer immunotherapy and viral vaccines Peter Selby FACP(UK) Richard Alan Steve Sasha Matt Nav Vile Melcher Griffin Zougman Bentham Vasudev Adel Nick Gemma Liz Samson Hornigold
More informationThe Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep
The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep invaders out of the body (pp. 772 773; Fig. 21.1; Table
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationChapter 7 Conclusions
VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy
More informationCytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,
Cytokines http://highered.mcgraw-hill.com/sites/0072507470/student_view0/chapter22/animation the_immune_response.html Cytokines modulate the functional activities of individual cells and tissues both under
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationShiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School
CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationImmunological Tolerance
Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for
More informationAdaptive Immune System
Short Course on Immunology Adaptive Immune System Bhargavi Duvvuri Ph.D IIIrd Year (Immunology) bhargavi@yorku.ca Supervisor Dr.Gillian E Wu Professor, School of Kinesiology and Health Sciences York University,
More informationT Cell Effector Mechanisms I: B cell Help & DTH
T Cell Effector Mechanisms I: B cell Help & DTH Ned Braunstein, MD The Major T Cell Subsets p56 lck + T cells γ δ ε ζ ζ p56 lck CD8+ T cells γ δ ε ζ ζ Cα Cβ Vα Vβ CD3 CD8 Cα Cβ Vα Vβ CD3 MHC II peptide
More informationT Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
More informationDEVELOPMENT OF CELLULAR IMMUNOLOGY
DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationDendritic Cell Based Immunotherapy for Cancer. Edgar G. Engleman, M.D.
Dendritic Cell Based Immunotherapy for Cancer Edgar G. Engleman, M.D. Two main DC subsets Myeloid (mydc) Derived from monocytes Capture/process/present Ag to T cells Activate NK cells and B cells Plasmacytoid
More informationAdaptive Immunity: Specific Defenses of the Host
17 Adaptive Immunity: Specific Defenses of the Host SLOs Differentiate between innate and adaptive immunity, and humoral and cellular immunity. Define antigen, epitope, and hapten. Explain the function
More informationCellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU
Cellular Immune response Jianzhong Chen, Ph.D Institute of immunology, ZJU Concept of adaptive immune response T cell-mediated adaptive immune response I. Concept of immune response A collective and coordinated
More informationTherapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler
Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler Goal of Immunotherapy Boosting the low level anti-tumor immune
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationUnderstanding basic immunology. Dr Mary Nowlan
Understanding basic immunology Dr Mary Nowlan 1 Immunology Immunology the study of how the body fights disease and infection Immunity State of being able to resist a particular infection or toxin 2 Overview
More informationAll animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity
1 2 3 4 5 6 7 8 9 The Immune System All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity Figure 43.2 In innate immunity, recognition and
More informationEffector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells
ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction
More informationT cells III: Cytotoxic T lymphocytes and natural killer cells
T cells III: Cytotoxic T lymphocytes and natural killer cells Margrit Wiesendanger Division of Rheumatology, CUMC September 17, 2008 Killer cells: CD8 + T cells (adaptive) vs. natural killer (innate) Shared
More informationمحاضرة مناعت مدرس المادة :ا.م. هدى عبدالهادي علي النصراوي Immunity to Infectious Diseases
محاضرة مناعت مدرس المادة :ا.م. هدى عبدالهادي علي النصراوي Immunity to Infectious Diseases Immunity to infection depends on a combination of innate mechanisms (phagocytosis, complement, etc.) and antigen
More informationLAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies
LAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies Cancer immunotherapy has emerged as a clinically validated tool for fighting certain kinds of cancers. These therapeutic cancer vaccines
More informationChapter 43. Immune System. phagocytosis. lymphocytes. AP Biology
Chapter 43. Immune System phagocytosis lymphocytes 1 Why an immune system? Attack from outside lots of organisms want you for lunch! animals must defend themselves against unwelcome invaders viruses protists
More informationLecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells
1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationMicro 204. Cytotoxic T Lymphocytes (CTL) Lewis Lanier
Micro 204 Cytotoxic T Lymphocytes (CTL) Lewis Lanier Lewis.Lanier@ucsf.edu Lymphocyte-mediated Cytotoxicity CD8 + αβ-tcr + T cells CD4 + αβ-tcr + T cells γδ-tcr + T cells Natural Killer cells CD8 + αβ-tcr
More informationchapter 17: specific/adaptable defenses of the host: the immune response
chapter 17: specific/adaptable defenses of the host: the immune response defense against infection & illness body defenses innate/ non-specific adaptable/ specific epithelium, fever, inflammation, complement,
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationCell Mediated Immunity CELL MEDIATED IMMUNITY. Basic Elements of Cell Mediated Immunity (CMI) Antibody-dependent cell-mediated cytotoxicity (ADCC)
Chapter 16 CELL MEDIATED IMMUNITY Cell Mediated Immunity Also known as Cellular Immunity or CMI The effector phase T cells Specificity for immune recognition reactions TH provide cytokines CTLs do the
More informationDefensive mechanisms include :
Acquired Immunity Defensive mechanisms include : 1) Innate immunity (Natural or Non specific) 2) Acquired immunity (Adaptive or Specific) Cell-mediated immunity Humoral immunity Two mechanisms 1) Humoral
More information